Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Beechhurst, are you an investment philosopher, lol? You think your A4 waffle posts with some technical terms and figures you call “article” lol, make you a stock market guru? Why don’t publish them in investments academic journal for a wider audience? I’d recommend “Farting from the Brain Journal” lol
PhatStyle4321, give up your pathetic deramping you’re too transparent idiot. Sex paid for by the NHS, who wouldn’t want to try it lol? Watch the sp go up by 25% today ……and more by end of week
PhatStyle4321, are you thinking straight PhatStyle4321? You might need some get on your brain lol. People on benefits, low income and pensioners will get it for free. So it increase the demands significantly particularly this will be a repeat prescription for obvious reason lol. What’s the population of these categories of these customers? Off the top of my head 8-10 millions?
PhatStyle4321, no Fum receives the full price as all medicines are subsidised by the government. What’s more, people on benefits, low income and pensioners get it for free; so they will just be ordering it non stop til their ‘heart’ content lol. What’s the number of these people 7-10 millions? That’s your potential customers with no marketing and payments for them, the revenues of which Fum is mind boggling.
Toli, please don’t twist my words with your pathetic agenda. Those weird sells of £10.01k aren’t ordinary sells. But maybe designed to help IIs to build stake a cheaper price. So overall it’s a positive thing, as MMs will walk the sp up eventually. With news of more countries launching Eroxon anytime now not till April the sp is on the upward trajectory. The product is started selling in Germany and France this week with 12 countries altogether in the pipeline, so i’d expect an rns anytime now.
The price paid would suggest a buy. This fall is either people selling to pike into Bitcoin as it broke $50k last night, or to fill an IIs order. Yesterday we had £100k and £45k, both suggesting IIs. So MMs drop the price to get sell to fill IIs orders me thinks. The sp trajectory is upwards with the expected news.
Good start and bodes well for this week. I’d say 60p by Wednesday at the latest. We should have more IIs building a stake, as we saw one on Friday imo. The fact they already started selling in France & Italy so soon after last week rns, 2 of the 12 countries in which they’re launching including Saudi Arabia will help keep the momentum upwards strongly. The Saudis have plenty of money and time, they’d be buying Eroxon like candies if only to play games of tease one another lol.
And why should your opinion of me matter, when you were expecting the sp to drift down from 38p lol. Now go play computer games, or watch cartoons, Leave investment to grown up and no need to reply I don’t waste my valuable time with village idiots, hence I don’t post much.
“ DarthInvester
Posted in: FUM
Posts: 732
Price: 38.10
No Opinion
RE: Proactive Investors Post6 Feb 2024 16:45
Shame.it's a long wait to april. Profit takers will hit and the sp may drift back down until then.... unless more rns out about more launches to keep momentum up.“
Nice rise yeah, lol. I’ve been saying rerate was coming with IIs piling in. IIs take few days from the update as they’ve to juggle their investments including selling elsewhere to invest in FUM given the excellent update on soft launch with a lot of news from now til April. I wouldn’t surprised 60p by mid next week, as more IIs get in.
That’s the start of the rerate i was talking about earlier, yesterday and the day before. All the lights are on, looking at the update and understanding the market behaviour. By end of next week sp should be up minimum 50%.
The 3 purchases at the same time 9:1 am for £12k, £25k, £30k strike me a IIs piling in. They haven’t finished, they have going in by small stakes not to disrupt the market. and we will see other IIs following in their steps soon.
Relistening to the interview Barber it’s actually 12 countries inc Saudi Arabia in addition to the 10 EU countries. This is a the start of the rerate expected with the update with a period of news til April. The share price should be in a very interesting territory by next week and beyond after some IIs have digested the update with the huge potential and piled in.
DancingDime, in your books a YouTuber Maliks has more credibility than the FDA and Haleon, the world biggest OTC consumer healthcare company, who has paid an initial £4million upfronts and taken up all the cost for marketing etc… in the US. You don’t think they did their due diligence? Are you that simpleton hence registered on lse since 2020 and posted only 13 times in 3 years and ONLY on Fum, no other shares?
DancingDime, the sp halving over the last year has done remarkably well comparatively. The majority of small caps have fallen by 90%. Aren’t you aware of the bear market started by covid then extended by the Ukraine war with inflation around the world surpassing 10? Any student in investment seems to be aware of that, except you it’d seem.
I suppose allowing the fake Erexon to be sold in the US before Haleon is ready is free marketing til they launch the real product and attack those behind the fake one lol. Business is all about making money sometimes in a devious way, including having fake erection just like when women fake orgasm lol. The sp is about to erect big, or is that rerate in normal parlance lol
From across the pond:
“Citywire view;
"Current SP implies Futura will take less than 4% of European ED market and none of US market - these assumptions are completely at odds with progress to date with Eroxon taking 20% of the UK/Belgium markets" dyor etc
Up to now, all ED viagra type treatments need GP prescriptions so size of the market = value of prescriptions used by the population.
We are offering a non prescription product which creates a new market altogether - ultimately the size of the total ED market will be defined as Eroxon Otc + GP prescribed treatments. Now this has been validated as entirely successful the advertising and PR is being scaled up alongside wider global launches.
I suspect we will get a much better idea of growth of the market perhaps by June 2024 in UK with wider availability in stores, online pharmacies with full marketing spend behind it. That is the time to say what longer term growth trajectory looks like.
Imvho and dyor etc“